Cipher Pharmaceuticals Inc. (CPH.TO)
CAD 14.04
(-2.23%)
CAD 14.04
(-2.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -39.47 Million USD | -38.95% |
| 2022 | -28.4 Million USD | -41.81% |
| 2021 | -20.03 Million USD | -174.67% |
| 2020 | -7.29 Million USD | -326.35% |
| 2019 | 3.22 Million USD | -55.32% |
| 2018 | 7.21 Million USD | 171.26% |
| 2017 | -10.12 Million USD | -635.22% |
| 2016 | 1.89 Million USD | -74.43% |
| 2015 | 7.39 Million USD | 15644.02% |
| 2014 | -47.58 Thousand USD | 99.79% |
| 2013 | -22.7 Million USD | -42.59% |
| 2012 | -15.92 Million USD | -68.74% |
| 2011 | -9.43 Million USD | 8.6% |
| 2010 | -10.32 Million USD | -20.06% |
| 2009 | -8.6 Million USD | -5.93% |
| 2008 | -8.11 Million USD | 26.65% |
| 2007 | -11.06 Million USD | 14.43% |
| 2006 | -12.93 Million USD | 9.59% |
| 2005 | -14.3 Million USD | -2.77% |
| 2004 | -13.92 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -41.65 Million USD | -5.54% |
| 2024 Q2 | -47.68 Million USD | -14.48% |
| 2023 Q4 | -39.47 Million USD | 5.42% |
| 2023 Q3 | -41.73 Million USD | -16.08% |
| 2023 FY | -39.47 Million USD | -38.95% |
| 2023 Q1 | -33.02 Million USD | -16.25% |
| 2023 Q2 | -35.95 Million USD | -8.87% |
| 2022 Q4 | -28.4 Million USD | -5.09% |
| 2022 FY | -28.4 Million USD | -41.81% |
| 2022 Q1 | -21.32 Million USD | -6.46% |
| 2022 Q2 | -23.68 Million USD | -11.06% |
| 2022 Q3 | -27.03 Million USD | -14.13% |
| 2021 Q3 | -15.62 Million USD | -10.1% |
| 2021 FY | -20.03 Million USD | -174.67% |
| 2021 Q2 | -14.19 Million USD | -24.06% |
| 2021 Q4 | -20.03 Million USD | -28.18% |
| 2021 Q1 | -11.44 Million USD | -56.89% |
| 2020 Q1 | -1.44 Million USD | -144.85% |
| 2020 Q3 | -1.27 Million USD | 60.88% |
| 2020 Q4 | -7.29 Million USD | -473.8% |
| 2020 FY | -7.29 Million USD | -326.35% |
| 2020 Q2 | -3.24 Million USD | -124.84% |
| 2019 Q1 | 7.61 Million USD | 5.53% |
| 2019 Q4 | 3.22 Million USD | -49.31% |
| 2019 Q3 | 6.35 Million USD | -16.77% |
| 2019 Q2 | 7.63 Million USD | 0.34% |
| 2019 FY | 3.22 Million USD | -55.32% |
| 2018 Q2 | 8.84 Million USD | 176.87% |
| 2018 FY | 7.21 Million USD | 171.26% |
| 2018 Q4 | 7.21 Million USD | -23.5% |
| 2018 Q3 | 9.42 Million USD | 6.59% |
| 2018 Q1 | -11.5 Million USD | -13.67% |
| 2017 FY | -10.12 Million USD | -635.22% |
| 2017 Q4 | -10.12 Million USD | -119.16% |
| 2017 Q2 | -52 Thousand USD | -100.9% |
| 2017 Q1 | 5.8 Million USD | 206.72% |
| 2017 Q3 | -4.61 Million USD | -8780.77% |
| 2016 FY | 1.89 Million USD | -74.43% |
| 2016 Q2 | 4.38 Million USD | -27.75% |
| 2016 Q3 | 5.38 Million USD | 22.69% |
| 2016 Q4 | 1.89 Million USD | -64.86% |
| 2016 Q1 | 6.07 Million USD | -17.92% |
| 2015 FY | 7.39 Million USD | 15644.02% |
| 2015 Q1 | -37.12 Million USD | 18.11% |
| 2015 Q4 | 7.39 Million USD | 17.04% |
| 2015 Q3 | 6.31 Million USD | 50.1% |
| 2015 Q2 | 4.21 Million USD | 111.34% |
| 2014 Q3 | -42.62 Million USD | -14.54% |
| 2014 Q4 | -45.33 Million USD | -6.36% |
| 2014 Q1 | -31.2 Million USD | -37.44% |
| 2014 FY | -47.58 Thousand USD | 99.79% |
| 2014 Q2 | -37.21 Million USD | -19.25% |
| 2013 Q3 | -19.42 Million USD | -14.96% |
| 2013 Q4 | -22.7 Million USD | -16.92% |
| 2013 FY | -22.7 Million USD | -42.59% |
| 2013 Q1 | -16.23 Million USD | -1.94% |
| 2013 Q2 | -16.89 Million USD | -4.06% |
| 2012 FY | -15.92 Million USD | -68.74% |
| 2012 Q3 | -15.32 Million USD | -8.2% |
| 2012 Q2 | -14.16 Million USD | -39.71% |
| 2012 Q1 | -10.13 Million USD | -7.4% |
| 2012 Q4 | -15.92 Million USD | -3.94% |
| 2011 Q3 | -8.89 Million USD | -0.54% |
| 2011 Q2 | -8.85 Million USD | 5.95% |
| 2011 FY | -9.43 Million USD | 8.6% |
| 2011 Q4 | -9.43 Million USD | -6.05% |
| 2011 Q1 | -9.41 Million USD | 8.86% |
| 2010 Q3 | -10.21 Million USD | -4.42% |
| 2010 Q2 | -9.78 Million USD | -9.3% |
| 2010 Q4 | -10.32 Million USD | -1.11% |
| 2010 FY | -10.32 Million USD | -20.06% |
| 2010 Q1 | -8.94 Million USD | -4.04% |
| 2009 Q3 | -8.73 Million USD | -5.32% |
| 2009 FY | -8.6 Million USD | -5.93% |
| 2009 Q2 | -8.29 Million USD | -15.11% |
| 2009 Q1 | -7.2 Million USD | 11.21% |
| 2009 Q4 | -8.6 Million USD | 1.59% |
| 2008 Q2 | -9.67 Million USD | 3.0% |
| 2008 Q4 | -8.11 Million USD | 16.37% |
| 2008 Q3 | -9.7 Million USD | -0.3% |
| 2008 FY | -8.11 Million USD | 26.65% |
| 2008 Q1 | -9.97 Million USD | 9.85% |
| 2007 Q3 | -12.14 Million USD | -6.4% |
| 2007 Q4 | -11.06 Million USD | 8.85% |
| 2007 FY | -11.06 Million USD | 14.43% |
| 2007 Q1 | -11.82 Million USD | 8.6% |
| 2007 Q2 | -11.41 Million USD | 3.47% |
| 2006 FY | -12.93 Million USD | 9.59% |
| 2006 Q4 | -12.93 Million USD | 14.91% |
| 2006 Q2 | -17.48 Million USD | 14.6% |
| 2006 Q3 | -15.2 Million USD | 13.06% |
| 2006 Q1 | -20.47 Million USD | -43.11% |
| 2005 Q3 | -16.81 Million USD | 20.5% |
| 2005 Q1 | -22.5 Million USD | 0.0% |
| 2005 Q4 | -14.3 Million USD | 14.92% |
| 2005 FY | -14.3 Million USD | -2.77% |
| 2005 Q2 | -21.15 Million USD | 6.03% |
| 2004 Q2 | -18.3 Million USD | 16.84% |
| 2004 Q1 | -22.01 Million USD | 0.0% |
| 2004 FY | -13.92 Million USD | 0.0% |
| 2004 Q3 | -15.26 Million USD | 16.64% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | -8.64 Million CAD | -356.429% |
| Avicanna Inc. | 1.32 Million CAD | 3076.326% |
| Avant Brands Inc. | 17.93 Million CAD | 320.145% |
| Cardiol Therapeutics Inc. | -34.77 Million CAD | -13.513% |
| Crescita Therapeutics Inc. | -8.13 Million CAD | -385.451% |
| Knight Therapeutics Inc. | 10.33 Million CAD | 482.11% |
| MediPharm Labs Corp. | -15.68 Million CAD | -151.638% |
| OrganiGram Holdings Inc. | -33.7 Million CAD | -17.096% |
| Canopy Growth Corporation | 512.87 Million CAD | 107.696% |
| Willow Biosciences Inc. | -989 Thousand CAD | -3891.102% |
| Auxly Cannabis Group Inc. | 142.88 Million CAD | 127.626% |